Keresés eredménye

Típusa:

összetett keresés

Keresési paraméterek:

Hang Quach, MD | szakcikk |

A zárolt tartalmakat csak bejelentkezett felhasználók tekinthetik meg!

1875 Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of MaiaClinically Relevant Abstract

Szerző: Nizar Bahlis, MD¹ Thierry Facon, MD² Saad Z. Usmani, MD³ Shaji K. Kumar, MD⁴ Torben Plesner, MD, DSc⁵ Robert Z. Orlowski, MD, PhD⁶ Cyrille Touzeau, MD⁷ Supratik Basu, MBBS, MD, FRCP, FRCPath⁸ Hareth Nahi, MD, PhD⁹ Cyrille Hulin, MD¹⁰ Hang Quach, MD¹¹ Hartmut Goldschmidt¹² Michael E O'Dwyer, MD¹³ Christopher P Venner, MD¹⁴ Katja C. Weisel, MD¹⁵ Maria Krevvata, PhD¹⁶ Huiling Pei, PhD¹⁷ Jianping Wang¹⁸ Rian Van Rampelbergh¹⁹ Jon Ukropec, PhD²⁰ Clarissa M. Uhlar²¹ Rachel Kobos, MD²² Aurore Perrot²³
¹University of Calgary, Arnie Charbonneau Cancer Institute, Calgary, AB, Canada
²Service des Maladies du Sang, Hôpital Claude Huriez, Lille, France
³Levine Cancer Institute/Atrium Health, Charlotte, NC
⁴Division of Hematology, Mayo Clinic, Rochester, MN
⁵Vejle Hospital and University of Southern Denmark, Vejle, Denmark
⁶Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
⁷Hematology, University Hospital Hôtel-Dieu, Nantes, France
⁸Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, United Kingdom
⁹Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden
¹⁰Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France
¹¹St. Vincent's Hospital, Melbourne, Australia
¹²University Hospital Heidelberg and National Center of Tumor Diseases (NCT), Heidelberg, Germany
¹³Dept. of Medicine/Haematology, NUI, Galway, Ireland
¹⁴Division of Medical Oncology, University of Alberta, Edmonton, AB, Canada
¹⁵Medical Center of Hamburg-Eppendorf, Hamburg, Germany; University of Tuebingen, Tuebingen, Germany
¹⁶Janssen Research & Development, LLC, Spring House, PA
¹⁷Janssen Research & Development, LLC, Titusville, NJ
¹⁸Janssen Research & Development, LLC, Raritan, NJ
¹⁹Janssen Research & Development, Beerse, Belgium
²⁰Janssen Global Medical Affairs, Horsham, PA
²¹Janssen Research & Development, LLC, Spring House, PA
²²Janssen Research & Development, LLC, Raritan, NJ
²³Hematology Department, University Hospital, Vandoeuvre Les Nancy, France

Conclusion: After longer follow up, the addition of DARA to Rd continues to demonstrate a significant PFS benefit and improved rates of deeper and more durable responses vs Rd alone in patients with transplant-ineligible NDMM. The longer follow-up also demonstrated a significant improvement in PFS2 favoring D-Rd, and no new safety concerns were observed. These results continue to support the use of D-Rd in the first line of treatment for ...

LBA-6 Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03

Szerző: Saad Z. Usmani, MD, MBBS¹ Hang Quach, MD² María-Victoria Mateos³ Ola Landgren, MD, PhD⁴ Xavier Leleu, MD, PhD⁵ David S. Siegel⁶ Katja Weisel⁷ Hui Yang⁸ Zandra K. Klippel, MD⁹ Anita Zahlten-Kumeli¹⁰ Meletios A. Dimopoulos, MD¹¹
¹Atrium Health, Charlotte, NC
²St. Vincent's Hospital, Melbourne, Australia
³University Hospital Salamanca/IBSAL, Salamanca, Spain
⁴Memorial Sloan Kettering Cancer Center, New York, NY
⁵Hopital Claude Huriez, Lille, France
⁶John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ
⁷Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
⁸Amgen, Inc., Thousand Oaks, CA
⁹Amgen, Inc., Thousand Oaks, CA
¹⁰Amgen, Inc., Thousand Oaks, CA
¹¹National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Introduction: The use of lenalidomide (LEN) and bortezomib (BTZ) in newly diagnosed multiple myeloma (MM) patients (pts), along with continuous or maintenance therapy paradigm have improved survival outcomes. However, many pts progress while on these agents or discontinue them due to toxicity. There is a need for novel, efficacious, and tolerable regimens that can treat MM pts who are exposed or refractory to LEN or BTZ. The proteasome inhibitor ...

A zárolt tartalmakat csak bejelentkezett felhasználók tekinthetik meg!